Reata Pharmaceuticals — Corporate Update (November 2019)
17 slides from Reata Pharmaceuticals's corporate update, Nov 12, 2019
Slide 1: Management call to discuss positive topline pivotal Year 1 CARDINAL data
Management call to discuss Positive topline pivotal Year 1 CARDINAL Data Exhibit 99.3
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Alport Syndrome is a Severe, Inherited Form of CKD
Alport Syndrome is a Severe, Inherited Form of CKD Estimated Prevalence Alport syndrome is the second most common inherited cause of kidney failure1,2 Collagen mutations drive mitochondrial dysfunction, inflammation, and fibrosis3,4 In most severe forms of disease, median age for kidney failure is 2
Slide 4: Alport Syndrome Patients Rapidly Progress to ESKD
Alport Syndrome Patients Rapidly Progress to ESKD Diabetic CKD1 Hypertensive CKD2 ADPKD3 Alport4 Syndrome Average Annual Kidney Function Decline on Standard of Care 1Perkovic et al. 2018 CANVAS; 2Wright et al. 2002 AASK; 3Torres et al. 2017 REPRISE; 4CARDINAL Phase 3 placebo arm 5Assuming baseline e
Slide 5: Approved and Widely Used CKD Drugs Slow the Rate of eGFR Decline
Approved and Widely Used CKD Drugs Slow the Rate of eGFR Decline Standard of care treatments for CKD include ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs) and SGLT2 inhibitors In registrational studies, these drugs slow, but do not stop eGFR decline eGFR over time in both the placebo a
Slide 6: Tolvaptan Also Only Slows the Rate of eGFR Decline
Tolvaptan Also Only Slows the Rate of eGFR Decline 1.27 mL/min Tolvaptan in ADPKD Retained eGFR Benefit1 Tolvaptan recently approved for ADPKD using eGFR change after withdrawal of drug, the retained eGFR benefit Same registrational endpoint as CARDINAL Phase 3 study In its registrational REPRISE st
Slide 7: CARDINAL Endpoints: eGFR Improvement On and Off Treatment
CARDINAL Endpoints: eGFR Improvement On and Off Treatment FDA guided Reata that retained eGFR benefit versus placebo at one year of treatment may support accelerated approval and after two years may support full approval Consistent with tolvaptan precedent FDA provided us with similar guidance for o
Slide 8: CARDINAL Phase 3: Pivotal Study Design
CARDINAL Phase 3: Pivotal Study Design International, double-blind, placebo-controlled, randomized, registrational trial Largest interventional study in patients with AS Enrolled a wide and representative range of patients with AS eGFR: 30 to 90 ml/min Age: 12 to 70 years After 52 weeks, patients re
Slide 9: Demographics and Baseline Disease Characteristics
Demographics and Baseline Disease Characteristics Characteristic (Mean ± SD) Placebo (n=80) Bard (n=77) Male (n,%) 32 (40%) 34 (44%) Age 39.6 ± 16.0 38.8 ± 14.6 <18 (n,%) 12 (15%) 11 (14%) eGFR (mL/min/1.73 m2) 62.6 ± 18.2 62.7 ± 17.7 ≤60 (n,%) 33 (41%) 33 (43%) >60 (n,%) 47 (59%) 44 (57%) Albumin t
Slide 10: CARDINAL Met the Primary Endpoint
CARDINAL Met the Primary Endpoint Bard treatment significantly improved on-treatment eGFR at Week 48 by 9.50 ml/min relative to placebo (p<0.0001) Placebo patients had significant kidney function loss versus baseline (p=0.0002)* Bard significantly improved eGFR (p=0.0004)* versus baseline p<0.0001 P
Slide 11: CARDINAL Met Key Secondary Endpoint
CARDINAL Met Key Secondary Endpoint Bard treatment significantly improved off-treatment eGFR at Week 52 by 5.14 ml/min relative to placebo (p=0.0012) Placebo patients had significant kidney function loss relative to baseline (p<0.0001)* Bard patients had a slight, non-significant decline relative to
Slide 12: Bard Treatment Produced Benefit Across All Quartiles of Response
Bard Treatment Produced Benefit Across All Quartiles of Response Week 48 eGFR Change Mean ± SD Week 52 eGFR Change Mean ± SD ∆eGFR Quartile Placebo Bard Placebo Bard 1 4.2 ± 2.4 20.9 ± 11.5 5.0 ± 4.2 12.9 ± 8.1 2 -1.3 ± 1.4 9.2 ± 2.4 -2.5 ± 1.4 2.5 ± 1.6 3 -5.7 ± 1.5 1.7 ± 2.2 -7.4 ± 2.3 -3.2 ± 1.7
Slide 13: Summary of Safety
Summary of Safety Fewer SAEs reported in Bard patients No fluid overload or major adverse cardiac events in patients treated with Bard Blood pressure decreased relative to baseline in the Bard group but was not significantly different between groups Overall low rate of cardiac and vascular AEs that
Slide 14: Summary and Next Steps
Summary and Next Steps The Phase 3 portion of CARDINAL met its primary endpoint (p<0.0001) The Phase 3 portion of CARDINAL met its precedented, registrational key secondary endpoint (p=0.0012) Bard treatment effectively slowed or halted decline in eGFR in patients with rapidly progressing CKD Approx
Slide 15: Reata Pharmaceuticals
s°s REATA | aaa ee PHARMACEUTICALS
Slide 16: An Eventful Q4
An Eventful Q4 On October 10, we announced that we had reacquired the rights to develop Bard, Omav and our other Nrf2 activators On October 11, we announced the presentation at ASN of several important studies, including the Kashihara work demonstrating the precise mechanism of GFR improvement from
Slide 17: Poised to Develop Franchises in CKD and Neurological Disease
Poised to Develop Franchises in CKD and Neurological Disease Global Opportunity Reata possesses WW commercial rights to all pipeline assets* Few or no effective therapies currently approved for lead indications Bardoxolone in Rare Forms of CKD Positive pivotal data in Alport syndrome Pipeline in rar
Reata Pharmaceuticals — Corporate Update (November 2019) on 6ix